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ABSTRACT 
BACKGROUND:  Aging is associated with increased lipid peroxidation (LP). 
D-003, a mixture of long-chain aliphatic primary acids purified from sugar cane wax, 
has been found to inhibit LP in experimental models and in healthy subjects. 
OBJECT IVES:  The aim of this study was to assess the effects of D-003 on LP 
markers and the lipid profile of older individuals. 
METHODS:  This randomized, double-blind, placebo-controlled study was con- 
ducted at the Plaza Veterans' House, Havana City, Cuba. Male and female patients aged 
>60 years with total cholesterol values of <6.1 mmol/L were eligible for inclusion in the 
study. After a 3-week lead-in and baseline assessment period, patients were randomized 
to receive PO D-003 5 mg/d, D-003 10 mg/d, or placebo for 8 weeks. The effect on 
copper-induced LP of low-density lipoprotein (LDL) particles was the primary vari- 
able, and the effects on plasma total antioxidant status (TAS), plasma malondialdehyde 
(MDA) concentration, plasma antioxidant enzyme (superoxide dismutase and gluta- 
thione peroxidase) activities, and the lipid profile were secondary variables. A clinical 
examination was performed at each visit (baseline, weeks 4 and 8). A clinical exami- 
nation, LP, and blood tests (lipid profile, hematologic, and blood biochemistry safety 
indicators) were performed at baseline and after 8 weeks of treatment. Compliance and 
adverse vents (AEs) were assessed at weeks 4 and 8. A 2-tailed P < 0.05 was considered 
statistically significant for comparisons of both continuous and categoric variables. 
RESULTS:  Fifty-four patients aged >60 years were assessed for inclusion in the 
study, and 51 patients (40 women, 11 men; mean [SD] age, 67 [6] years) were included 
in the study. The lag phase of conjugated iene formation increased significantly and 
in a dose-dependent manner in the group treated with D-003 5 mg (24.7%; P < 0.01) 
and in the group treated with D-003 10 mg (29.3%; P < 0.01) compared with placebo. 
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The maximal rate of conjugated diene propagation decreased significantly in the D-003 
5- and 10-mg groups ~22.7% and 25.8%, respectively; both, P < 0.05) compared with 
placebo. TAS increased significantly (17.7% and 23.0%, respectively; both, P < 0.01) 
in both active treatment groups compared with placebo. Plasma MDA concentration 
decreased significantly in the D-003 10-mg group ~28.6%; P < 0.05) but not in the 
D-003 5-mg group, compared with placebo. These changes were also significant com- 
pared with baseline. Antioxidant enzyme activities did not change in the active treat- 
ment groups compared with placebo r baseline. In the D-003 5- and 10-mg groups, 
significant decreases were found in LDL cholesterol concentration ~15.8% and 23.8%, 
respectively; both, P < 0.001) and total cholesterol concentration G13.0% and 16.8%, 
both, P < 0.05) compared with placebo. High-density lipoprotein cholesterol concentra- 
tion increased significantly in the D-003 5-mg group (5.7%; P < 0.05) and the D-003 
10-mg group (18.2%; P < 0.001) compared with placebo. Changes in the lipid profile 
were also significant compared with baseline. In the placebo group, no variable changed 
significantly compared with baseline. D-003 was well tolerated at both dose levels, and 
no patient withdrew from the study. There were a total of 3 AEs reported: insomnia 
and acidity in 2 patients receiving placebo; and heartburn in 1 patient receiving D-003 
5 mg. 
CONCLUSIONS:  D-003 5 and 10 mg/d administered to these older individuals 
(aged >60 years) for 8 weeks inhibited LP of LDL and increased TAS in a dose- 
dependent manner, while plasma MDA concentration decreased in the patients receiv- 
ing D-003 10 mg/d only. D-003 was well tolerated at both doses. (Cuff Thef Res Clifl 
Exp. 2008;69:36 48) © 2008 Excerpta Medica Inc. 
KEY WORDS"  D-003, lipid peroxidation, antioxidant compounds, lipid-lowering, 
elderly, sugar cane wax acids. 
INTRODUCTION 
Because of increased life expectancy, elderly individuals are currently the fastest grow- 
ing segment of the population worldwide. 1 Atherosclerotic diseases (eg, coronary heart 
disease [CHD]) and cerebrovascular diseases are the main causes of mortality in older 
individuals. 2 An estimated 7.6 million people died from CHD and 5.7 million from 
stroke in 2005.2 Elevated serum low-density lipoprotein cholesterol (LDL-C) concentra- 
tions increase coronary risk3,4; but lowering LDL-C reduces coronary events in adults, 5 8 
including the elderly. 8 Although the benefit of lowering cholesterol concentration i
older individuals has been questioned, 9 the absolute risk of morbidity and mortality 
from CHD increases with age, and a high LDL-C concentration has been found to be a 
strong predictor of absolute coronary risk in the elderly>; the segment of the population 
with the highest rate of CHD. Updated guidelines 11 on cholesterol recommend manage- 
ment of serum LDL-C concentration i  these individuals. 
In addition to the pivotal role of increased LDL-C concentration asan atherogenic fac- 
tor, lipid peroxidation (LP) of LDL results in the formation of oxidized LDL (LDL-o). 
LDL-o is more atherogenic than LDL itself because it is scavenged by macrophages 
in an uncontrolled manner, triggering foam cell formation, which is the first step in 
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the formation of atherosclerotic lesions, and also because LDL-o is immunogenic and 
cytotoxic to the endothelium. 12 Considering the high frequency of atherosclerotic dis- 
eases in the elderly and the oxidative hypothesis of the aging process, treatments that 
concurrently prevent LDL oxidation and reduce serum LDL-C concentration might help 
prevent atherosclerosis and associated complications in this population. 
D-003 is a mixture of long-chain aliphatic primary acids purified from sugar 
cane wax. Octacosanoic acid is the most abundant component of D-003; followed by 
triacontanoic, dotriacontanoic, and tetratriacontanoic a ids, and lower concentration 
acids tetracosanoic, pentacosanoic, hexacosanoic, heptacosanoic, nonacosanoic, hentria- 
contanoic, tritiacontanoic, pentatriacontanoic, and hexatriacontanoic, all of which are 
within reproducible imits. 13 
D-003 has been found to inhibit LP in experimental models, 14 17 to increase the lag 
phase of conjugated iene formation, and to decrease the maximal rate (Vm~ x) of con- 
jugated diene propagation of LDL copper-induced peroxidation i  healthy volunteers, i  
D-003 has also been associated with cholesteroMowering effects in experimental nd 
clinical studies. 19,2° Other studies 21,22 have found that D-003 inhibits cholesterol synthesis 
prior to mevalonate formation through the regulation ofhydroxymethylglutaryl-coenzyme 
A reductase (HMG-CoA) activity in fibroblasts cultured in a lipid-depleted medium. 21 
D-003 was found to decrease plasma LDL-C concentration i  rabbits with hypercholes- 
terolemia ssociated with a casein-rich, fat-free diet. 21 D-003 was well tolerated in clinical 
trials, 19,2° and toxicologic studies 23 27 have not found treatment-related oxicity. 
The primary aim of this study was to assess whether D-003, administered at doses 
of 5 and 10 mg/d for 8 weeks, favorably changed LP markers in older individuals. The 
secondary aim of this study was to assess the effects of D-003 on the lipid profile. 
SUBJECTS AND METHODS 
STUDY DES IGN 
This randomized, ouble-blind, placebo-controlled study was conducted at the Plaza 
Veterans' House, Havana City, Cuba. The study protocol was approved by the Veterans' 
House independent e hics committee. 
Volunteers were recruited by in-house referrals at the outpatient department of the 
Plaza Veterans' House Surgical Medical Research Center. Patients were enrolled into 
the study after provided informed written consent. General data regarding sex, age, 
height, weight, personal history, and family history were collected and recorded, and 
subjects underwent a complete physical examination, including pulse rate and arterial 
pressure and laboratory tests (hemoglobin, hematocrit, blood red ceils, white blood 
cell and platelet counts, lipid profile and blood biochemistry safety indicators [fasting 
blood glucose, creatinine, and activities of aspartate and alanine aminotransferases], 
alkaline phosphatase, and creatine phosphokinase). Patients were instructed to adhere 
to a 3-week lead-in cholesteroMowering diet based on therapeutic lifestyle change recom- 
mendations. After this lead-in period, patients were randomized to receive D-003 5 mg/d, 
10 mg/d, or placebo for 8 weeks. A complete clinical examination was conducted at each 
visit. LP and blood tests (lipid profile, hematologic, and blood biochemistry safety 
indicators) were performed at baseline and after 8 weeks of treatment, while clinical 
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examination was performed, and compliance and adverse vents (AEs) were assessed at 
weeks 4 and 8. 
PAT IENTS 
Male and female outpatients aged >60 years with total cholesterol values of <6.1 mmol/L 
were eligible for inclusion in the study. After the lead-in period, patients were assessed 
and had to meet the following serum lipid profile criteria: total cholesterol (TC) <6.1, 
LDL-C >3.4, and triglycerides (TG) <4.52 mmol/L. Patients with active renal or hepatic 
disease, diagnosed neoplastic diseases, uncontrolled hypertension (diastolic pressure 
>100 mm Hg), or diabetes mellitus (fasting serum glucose concentration >7.5 mmol/L), 
and those who had used antioxidants within 3 months prior to the study were also 
excluded. Patients who had experienced unstable angina, myocardial infarction, stroke, 
transient ischemic attacks, coronary surgery, or who were hospitalized ue to other criti- 
cal events (eg, revascularization surgery or any major surgery) in the 6 months prior to 
the study were excluded as well. 
D-003 and placebo were identical in packaging. The treatments were coded by a 
computer-generated randomization scheme Clinstat (Martin Bland, London, United 
Kingdom), utilizing balanced blocks and a half-allocation ratio. Treatment tablets were 
administered once daily with the evening meal for 8 weeks. 
Concomitant consumption of supplements with antioxidant effects (ie, vitamin E, 
vitamin C, multivitamins containing vitamin E or C, and any flavonoid-rich supple- 
ments) or lipid-lowering drugs (ie, statins, fibrates, niacin, ionic-exchange r sins, fish oil 
omega-3 fatty acids, and phytosterols) was not allowed during the study. 
RESPONSE VARIABLES 
As LP markers, we assessed the effects of D-003 on LP of LDL (as per the effect on 
the kinetics of conjugated iene generation and propagation), as well as plasma total 
antioxidant status (TAS), plasma malondialdehyde (MDA) concentration, and plasma 
antioxidant enzyme (superoxide dismutase [SOD] and glutathione peroxidase [GSHPX]) 
activities. The primary efficacy variable was the effect on LDL copper-induced LP. The 
treatment was considered to have beneficial effects on LP if there was a significant 
increase in the length of the lag phase of diene generation and/or a significant decrease 
in the Vm~ x of >20% versus baseline and placebo. Effects on other LP markers and on 
the lipid profile were secondary efficacy variables. D-003 treatment was considered 
effective against hese LP markers if plasma serum TAS increased and/or thiobarbituric 
acid-reactant substance (TBARS) generation decreased versus baseline and placebo. 
D-003 treatment was considered effective in lowering cholesterol if a decrease of >15% 
in LDL-C concentration versus baseline and placebo was determined. 2s 
ASSESSMENT OF  EFFECTS ON PLASMA L IP ID  PEROXIDAT ION MARKERS 
After a 12-hour fast, venous blood samples were drawn again. Assays were conducted 
in triplicates. 
Plasma lipid peroxide concentration was assayed by measuring the TBARS con- 
centration. 29A 0.5 mL of plasma was added to a solution of 0.2 mL of 8.1% sodium 
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dodecyl sulfate, 1.5 mL of 20% acetic acid adjusted to pH 3.5, and 1.5 mL of an aqueous 
solution of thiobarbituric acid (TBA). The mixture was diluted to 4 mL with distilled 
water and heated to 95°C. To prevent he formation of TBA reactants during the assay, 
1 mM of butylated hydroxytoluene was added. After cooling, 1 mL of distilled water 
and 5 mL of n-butanol:pyridine (15:1 v/v) were added to the mixture, which was then 
mixed together and centrifuged at 4000 rpm for 20 minutes. The absorbance of the 
organic layer was measured at 532 nm. Freshly diluted MDA-bis (dimethyl acetal) was 
the reference standard. The concentration of lipid peroxide was reported as nmol of 
MDA/mL. 
Plasma TAS in freshly drawn serum was determined using reagent kits (Randox 
Laboratories, Ltd., Crumlin, United Kingdom). This measurement is determined by 
the reaction between 2,2-azido-di-(3-ethylbenzthiazoline sulfonate) (ABTS), a peroxi- 
dase (metmyoglobin), and H202, which produces a blue-green radical cation (ABTS+) 
detected at 600 nm. The antioxidant potential of plasma samples added to the incu- 
bation mixture (0.01 mL) was determined according to color suppression and was 
expressed in mmol/L. 
Whole plasma SOD activity was measured using reagent kits (Randox Laboratories, 
Ltd.) through the inhibition of the reaction of xanthine and xanthine oxidase with 
2-(4-iodophenyl)-3-(4-nitrophenol)-5-phenyltetrazolium chl ride to generate superoxide 
radicals, thereby producing formazan red. 
GSHPX activity in heparinized whole blood samples was measured using reagent 
kits (Randox Laboratories, Ltd.). Since GSHPX catalyzes the oxidation of glutathione 
by cumene hydroperoxide, the enzyme activity was measured indirectly. Oxidized 
glutathione reacts with glutathione reductase, and the amount of reduced glutathione 
was estimated through the concomitant oxidation of nicotinamide adenine dinucle- 
otide phosphate hydrogen to nicotinamide adenine dinucleotide phosphate at 340 nm. 
Enzyme activities were expressed as UI/mg Hb (SOD) and UI (GSHPX). 
The effects of D-003 on the LP of LDL were assessed according to Kleinveld et al. 3° 
Samples were collected into plastic tubes with 10% ethylenediaminetetraacetic acid 
(EDTA) (final concentration 0.1%), and LDL was isolated by discontinuing density- 
gradient ultracentrifugation (22 hours at 285,000g [maximum]) in an ultracentrifuge 
SW40 rotor (Beckman Coulter, Fullerton, California). The kinetic of Cu2+-induced LDL 
oxidation was measured according to Esterbauer et al. 31 Isolated LDL was exhaustively 
dialyzed against a 200-fold volume of EDTA-free phosphate-buffered saline (0.01 M 
phosphate, 0.15 M sodium chloride, and pH 7.4). After overnight dialysis, LDL was 
oxidized with copper sulfate 4 5 btM, a final concentration, i  a cell-free system, and 
the extent of LDL oxidation was determined by the amount of conjugated iene forma- 
tion, which was measured by the absorbance changes at 234 nm at 37°C over a 5-hour 
period. 
Data from conjugated iene generation were expressed as time course curves. The 
t lag (minutes) and Vm~ xvalues (optical density [OD x 10 2/min • mg of LDL protein) were 
estimated from the oxidation curve. The inter- and intra-assay CVs in our conditions 
have been previously described. 32The LDL protein concentration was estimated using 
a modification of the Lowry method. 33 
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OTHER LABORATORY TESTS 
Serum TC and TG concentrations were measured using enzymatic reagent kits (Randox 
Laboratories, Ltd.), high-density lipoprotein cholesterol (HDL-C) concentration was mea- 
sured as the amount of cholesterol in the supernatant after precipitating ~-lipoprotein, 34 
and LDL-C concentration was calculated using the Friedewald equation. 35
Hematologic safety indicators were determined using the hematological complex 
equipment, while blood biochemistry indicators were determined through enzymatic 
methods, using reagent kits (Randox Laboratories, Ltd.) in a Hitachi 419 (Hitachi, Ltd., 
Tokyo, Japan). Both equipments were located at the clinical laboratory of the Surgical 
Medical Research Center. 
TOLERABIL ITY  ASSESSMENTS 
Data from physical examination, laboratory analyses, and AEs were included in 
the tolerability analysis. Laboratory tolerability indicators included concentrations of
hemoglobin, hematocrit, red blood ceils, white blood cell and platelet counts, serum 
creatinine, fasting blood glucose, and serum activities of aspartate and alanine amino- 
transferases, alkaline phosphatase, and creatinine phosphokinase. 
An AE was defined as any undesirable experience, whether or not it was considered 
treatment related. AEs were classified as: mild discontinuation of treatment was 
not required; moderate treatment had to be discontinued or specific treatment was 
required; and serious event resulted in hospitalization or death. 
STAT IST ICAL  ANALYS IS  
All data were analyzed using intent-to-treat nalysis. To ensure apower of 80% based 
on the assumption that the highest dose should produce an increase in the lag phase and/ 
or a reduction in Vma x of >20% compared with placebo, with a 5% significance level, 
>15 patients were needed for each group. Additionally, to control for an -10% dropout rate, 
50 total patients were needed for the study. 
The Wilcoxon test for paired samples was used to make within-group comparisons 
of continuous variables. The Mann-Whitney U test was used to make between-group 
comparisons. The Fisher exact test was used to compare categoric variables. A 2-tailed 
P < 0.05 was considered statistically significant. Statistical analyses were performed 
using Statistics for Windows version 4.2 (Statsoft Inc., Tulsa, Oklahoma). 
RESULTS 
BASEL INE CHARACTERIST ICS  
Of the 54 patients eligible for inclusion in the study, 51 (40 women, 11 men; mean [SD] 
age, 67 [6] years) were included and randomized to one of the 3 groups. Three of the patients 
were excluded because of adverse laboratory findings (serum LDL-C [<3.4 mmol/L], 2; and 
fasting glucose [>7.5 mmol/I,], 1). Treatment groups were matched with respect o demo- 
graphics including concomitant treatment (Table I). 
EFFECTS ON L IP ID  PEROXIDATION MARKERS 
The LP markers were well balanced in all groups at randomization. After treatment, 
the LP markers were unchanged in the placebo group compared with baseline. The lag 
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phase of the conjugated diene formation increased significantly and in a dose-dependent 
manner in the group that received D-003 Omg and the group that received D-003 
10-rag compared with placebo (24.7% and 29.3%, respectively; P < 0.0O and P < 0.01, 
respectively) and baseline (P < 0.01 and P < 0.0O, respectively). The V x of conjugated 
diene propagation decreased significantly in the D-003 O- and 10-rag groups compared 
with placebo ~22.7% and 20.8%,  respectively; both, P < 0.01) and with baseline 
(both, P < 0.0O) (Table TT). 
TAS increased significantly and in a dose-dependent manner in the D-003 O- and 10-rag 
groups compared with placebo (17.7% and 23.0%, respectively; both, P < 0.0O) and with 
baseline (both, P < 0.01). Plasma MDA concentration decreased significantly in the D-003 
10-rag group compared with placebo (28.6%; P < 0.0O) and with baseline (P < 0.0O). 
D-003 Omg was not associated with significant changes in MDA concentration compared 
with placebo r baseline. Plasma SOD and GSHPX activities did not change in either treat- 
ment group (Table TT). 
EFFECTS ON L IP ID PROFILE 
At baseline, lipid profile variables were not statistically difterent between groups. 
No significant changes from baseline were found in the placebo group. After 8 weeks 
Table I. Baseline demographic and clinical characterist ics of patients (N = 51) .*  
D-O03 
Placebo 
5 mg/d 10 mg/d 
Characteristic (n = 17) (n = 17) (n = 17) 
Age, mean (SD), y 
Sex, no. (%) 
Female 
Male 
Body mass index, 
mean (SD), kg/m 2 









Calcium channel blockers 
Oral hypoglycemic drugs 
Anxiolytics 
69 (6) 66 (5) 67 (7) 
14 (82.4) 13 (76.5) 13 (76.5) 
3 (17.6) 4 (23.5) 4 (23.5) 
26.2 (2.2) 25.7 (2.8) 25.3 (2.6) 
11 (64.7) 10 (58.8) 10 (58.8) 
2 (11.8) 2 (11.8) 2 (11.8) 
1 (5.9) 1 (5.9) 2 (11.8) 
6 (35.3) 6 (35.3) 5 (29.4) 
2 (11.8) 3 (17.6) 2 (11.8) 
2 (11.8) 2 (11.8) 2 (11.8) 
1 (5.9) 1 (5.9) 2 (11.8) 
1 (5.9) 1 (5.9) 1 (5.9) 
0 2 (11.8) 1 (5.9) 
*There were no significant between-group differences. 
t Drugs used by _>3 subjects. 
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Table II. Vma x of d iene fo rmat ion  on the e f fec ts  of D-O03 5 and 10  mg/d  on lipid per- 
ox idat ion (LP) markers  in o lder individuals by t reatment  group. Data  are mean 
(SD),  
Baseline 8 Weeks % Change 
Copper-induced LP of 
LDL T lag, min 
Placebo 85.99 (16.49) 81.37 (24.28) -5 .4 
D-O03 5 mg/d 85.70 (21.33) 106.90 (30.66)*t 24.7 t 
D-O03 10 mg/d 88.20 (23.53) 114.05 (30.82) t¢ 29.3§ 
Propagation rate, 
OD X lO-2/min • mg 
of LDL protein 
Placebo 21.66 (8.42) 21.65 (6.91) -0.0 
D-O03 5 mg/d 19.40 (7.00) 15.00 (5.66)*§ -22.7§ 
D-O03 10 mg/d 21.95 (11.36) 16.29 (5.76)*t -25.8§ 
Total antioxidant status, 
mmol/L 
Placebo 0.82 (0.13) 0.80 (0.19) -2.4 
D-O03 5 mg/d 0.79 (0.15) 0.93 (0.20)¢ 17.7t 
D-O03 10 mg/d 0.78 (0.16) 0.96 (0.21)t¢ 23.0t 
Plasma malondialdehyde, 
nmol/mL 
Placebo 62.47 (17.75) 57.74 (24.27) -7.6 
D-O03 5 mg/d 65.33 (17.28) 58.51 (20.73) -10.4 
D-O03 10 mg/d 69.53 (17.52) 49.62 (14.23)* -28.6t  
Plasma superoxide dismutase, 
UI/mg hemoglobin 
Placebo 120.91 (41.48) 105.87 (44.66) - 
D-O03 5 mg/d 133.55 (35.16) 121.63 (57.76) - 
D-O03 10 mg/d 128.84 (24.18) 133.93 (50.04) - 
Plasma glutathione peroxidase, 
UI 
Placebo 143.84 (41.08) 177.32 (56.90) - 
D-O03 5 mg/d 160.61 (41.72) 159.60 (39.55) - 
D-O03 10 mg/d 159.88 (55.50) 167.14 (35.32) - 
LDL = low-density lipoprotein; OD = optical density. 
*P < 0.05 versus baseline (Wilcoxon test for paired samples). 
tp < 0.05 versus placebo (Mann-Whitney U test). 
CP < 0.01 versus baseline (Wilcoxon test for paired samples). 
§P < 0.01 versus placebo (Mann-Whitney U test). 
of treatment with D-003 5 and 10 mg, LDL-C concentration decreased significantly 
compared with placebo ~15.8% and 23.8%, respectively; both, P < 0.001) and with 
baseline (both, P < 0.001). TC concentration also decreased significantly compared 
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with placebo ~13.0% and 16.8%; both, P < 0.05) and with baseline (both, P < 0.001). 
HDL-C concentration i creased significantly in the D-003 5-mg group and the D-003 
10-mg group compared with placebo (5.7% and 18.2%, respectively; P < 0.05 and P < 
0.001, respectively) and baseline (P < 0.05 and P < 0.001, respectively). TG decreased 
modestly but significantly in the D-003 10-mg group compared with placebo and base- 
line (P < 0.05) (Table lll). 
TOLERABIL ITY 
Treatment was well tolerated at both dose levels. D-003 did not adversely 
aftect physical or blood chemistry findings (data not shown). There were no 
abnormal aboratory results, and no patient withdrew from the study. A total of 
3 patients experienced mild AEs insomnia and acidity (1 patient for each in the 
placebo group) and heartburn (1 patient in the D-003 5-mg group). 
DISCUSSION 
This study suggests that treatment with D-003 5 and 10 mg for 8 weeks was associated 
with dose-dependent beneficial effects on LP markers in older individuals that were 
consistent with previous data. 18,21 
Table III. Effects of D-O03 5 and 10 mg/d on the serum lipid profile in older individuals 
by treatment group. Data are mean (SD). 
Treatment Baseline 8 Weeks % Change 
LDUC, mmol/L 
Placebo 4.02 (0.22) 4.03 (0.19) 0.2 
D-O03 5 mg/d 4.04 (0.33) 3.40 (0.15) *t -15.8 t 
D-O03 10 mg/d 3.99 (0.26) 3.04 (0.14) *t -23.8 t 
Total cholesterol, mmol/L 
Placebo 5.73 (0.29) 5.76 (0.26) 0.5 
D-O03 5 mg/d 5.75 (0.28) 5.00 (0.11) *t -13.0¢ 
D-O03 10 mg/d 5.71 (0.26) 4.75 (0.12) *t -16.8¢ 
HDL-C, mmol/L 
Placebo 1.08 (0.18) 1.04 (0.13) -3.7 
D-O03 5 mg/d 1.05 (0.18) 1.11 (0.13) § 5.7¢ 
D-O03 10 mg/d 1.10 (0.21) 1.30 (0.16) *t 18.2 t 
Triglycerides, mmol/L 
Placebo 1.71 (0.63) 1.80 (0.49) 5.3 
D-O03 5 mg/d 1.81 (0.72) 1.69 (0.38) -6 .6 
D-O03 10 mg/d 1.83 (0.55) 1.63 (0.32) § -10.9¢ 
LDL-C = low-density lipoprotein cholesterol; HDL-C = high-density lipoprotein cholesterol. 
*P < 0.001 versus baseline (Wilcoxon test for paired samples). 
tp < 0.001 versus placebo (Mann-Whitney U test). 
~P < 0.05 versus placebo (Mann-Whitney U test). 
§P < 0.05 versus baseline (Wilcoxon test for paired samples). 
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The groups were well matched at baseline in terms of demographic and clinical 
characteristics. Although 40 of the patients (78.4%) were women, it reflected the com- 
position of the population attending the clinic. The percentage of women was similar 
in the 3 groups. Because the study groups were homogeneous at baseline and the LP 
markers were unchanged in the placebo group, the effects discussed here were probably 
associated with the treatment. 
At both doses, oral D-003 protected LDL particles against LP, as supported by the 
increase in the lag phase and the decrease in the Vma x of the conjugated diene generation 
time course of LDL copper-dependent LP. In vitro generation of conjugated ienes with 
copper was an adequate surrogate of oxidative stress in humans and correlated well with 
estimated in vivo LDL oxidation) 6 In particular, evidence supports adirect relationship 
between the susceptibility of LDL to in vitro oxidation and atherogenic r isks  
The aging process might enhance oxidative stress, leading to increased susceptibility 
of LDL to peroxidation, 38 with LDL-o triggering atherosclerosis and complications. 12 
Therefore, the preventive ffect of D-003 on the LP of LDL particles at doses that are 
also effective for lowering LDL-C is potentially beneficial to older individuals. 
Beyond the effects of D-003 on LP of the LDL molecule, the primary efficacy vari- 
able, D-003 also increased plasma TAS, which reflects the total antioxidant potential 
of plasma against oxidative attack by free radicals. This suggests that the water-soluble 
and nonwater-soluble antioxidant capacity of plasma might be increased with D-003. 
D-003 at 10 mg/d, but not at 5 mg/d, decreased the plasma concentration f MDA 
(a final product of LP breakdown), as measured by TBARS concentration. Nevertheless, 
because other compounds might interfere with the results, the specificity of measuring 
plasma MDA concentration using TBARS concentration is not sufficient. 39 Further 
studies are needed to investigate the effects of D-003 on plasma MDA concentration 
using direct estimation of MDA. 
The moderate ffects of D-003 5 mg and 10 mg on serum LDL-C and TC concen- 
trations found in this study, which were consistent with those reported previously, I7 19 
have been associated with the inhibition of cholesterol synthesis before mevalonate 
formation through the regulation of HMG-CoA reductase activity and the increase in 
plasma LDL clearance. 21,22 However, the mechanism by which D-003 increases erum 
HDL-C is unknown. 
D-003 10 mg/d (but not 5 mg/d) significantly reduced serum TG concentration 
compared with baseline (P < 0.05), while no such reduction was found in TG concen- 
tration in other studies of D-003.  I5 20 Nevertheless, ince the change was not signifi- 
cant versus placebo, it should not be considered meaningful. However, we believe that 
further studies should explore whether this effect occurs with higher doses and after 
longer treatment periods. 
We found that D-003 protected against copper-induced LP of LDL in vitro in a cell- 
free system, which included only factors intrinsic to LDL. However, the susceptibility 
of LDL to in vivo oxidation is also influenced by extrinsic factors in the LDL micro- 
environment, including the presence of native HDL. 4° Although the protective ffects 
of HDL against coronary risk were first thought to be associated with the removal 
of excess cholesterol from peripheral tissues via reverse cholesterol transport, 41recent 
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data 42 suggest hat HDL protects against atherosclerosis through other mechanisms, 
since LDL oxidation is prevented by the action of 2 HDL-associated enzymes, paraoxo- 
nase and arylesterase, which reduce the deleterious effects of LP on LDL. Considering 
that D-003 has been found to produce moderate to marked increases in serum HDL-C 
concentration i  both experimental and clinical studies, 14 19 we cannot disregard the 
possibility that its antioxidant effects are linked to such action. However, because iden- 
tifying the antioxidant mechanisms of D-003 was beyond the objectives of this study, 
this is merely speculative. 
CONCLUSIONS 
D-003 5 and 10 mg/d administered for 8 weeks inhibited the LP of LDL and increased 
TAS in a dose-dependent manner, while D-003 10 mg/d also reduced plasma MDA 
without modifying antioxidant enzyme activities. The treatment also lowered LDL-C 
and TC, raised HDL-C, and was well tolerated. 
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